In one paragraphArticle in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Adrian ValadezDepartment of Pharmacy Practice, Midwestern University, College of Pharmacy, Downers Grove, Illinois, USA.ORCID 0009-0003-4192-5229 Emma HarlanDepartment of Pharmacy Practice, Midwestern University, College of Pharmacy, Downers Grove, Illinois, USA.
Colin JeantetDepartment of Pharmacy Practice, Midwestern University, College of Pharmacy, Downers Grove, Illinois, USA.
Marc H ScheetzDepartment of Pharmacy Practice, Midwestern University, College of Pharmacy, Downers Grove, Illinois, USA.ORCID 0000-0002-1091-6130 Michael N NeelyKeck School of Medicine, University of Southern California, Los Angeles, California, USA.ORCID 0000-0002-1675-8276 Helen K DonnellyDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.ORCID 0000-0001-8827-8581 Richard G WunderinkDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Nathaniel J RhodesDepartment of Pharmacy Practice, Midwestern University, College of Pharmacy, Downers Grove, Illinois, USA.ORCID 0000-0002-0018-5434 Funding
Technology CoreU19AI135964 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LUIS A. Nunes AMARAL · 2018 to 2026
$24.7MThe Cell Phenotyping and Mouse CoreP01HL154998 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI KAREN M RIDGE · 2021 to 2026
$18.9MCRITICAL: Collaborative Resource for Intensive care Translational science, Informatics, Comprehensive Analytics, and LearningU01TR003528 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI CIMINO, JAMES J, LUO, YUAN · 2021 to 2024
$4.9MMechanisms of regulatory T cell-mediated recovery from severe viral pneumoniaR01HL149883 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Benjamin David Singer · 2020 to 2026
$4.1MSystems-based pharmacologic modelling to elucidate beta-lactam clinical pharmacodynamics and define optimal dosing regimens in severe pneumoniaR01AI158530 · NIAID · MIDWESTERN UNIVERSITY · PI Nathaniel James Rhodes · 2022 to 2026
$3.4MModeling the Incompleteness and Biases of Health DataR01LM013337 · NLM · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LUO, YUAN · 2020 to 2023
$1.3MDevelopment and Evaluation of CRRT-Specific Precision Dosing Models to Optimize Beta-Lactam Treatment for Patients with Hospital-Acquired PneumoniaR21AI174159 · NIAID · MIDWESTERN UNIVERSITY · PI RHODES, NATHANIEL JAMES · 2023 to 2024
$417kNCATS NIH HHS U01 TR003528NHLBI NIH HHS P01 HL154998NHLBI NIH HHS R01 HL149883NIAID NIH HHS R01 AI158530NIAID NIH HHS R21 AI174159NIAID NIH HHS U19 AI135964NIH HHS P01HL154998NIH HHS R01AI158530NIH HHS R01HL149883NIH HHS R01LM013337NIH HHS R21AI174159NIH HHS U01TR003528NIH HHS U19AI135964NLM NIH HHS R01 LM013337
6 · The paper itselfAbstract
Population pharmacokinetic (PK) models may not generalize across critically ill populations. We evaluated the transportability of published parametric and nonparametric meropenem models as Bayesian priors. Seven published meropenem models were implemented in Monolix 2024R1. Nonparametric models were converted to log-normal priors from reported medians and CV%. An independent cohort was used for evaluation.
Indexed as
Anti-Bacterial AgentsMeropenemPneumoniaAgedBayes TheoremContinuous Renal Replacement TherapyCritical IllnessFemaleHumansMaleMiddle AgedModels, BiologicalAnti-Bacterial AgentsMeropenembayesian modelexternal validationpharmacokineticspneumoniarenal replacement
Identifiers
PMID42429782
PMCPMC13436005
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390